Abstract 4227
Background
Tumor-associated macrophages (TAMs) are a major component of innate immunity supporting primary tumor growth and metastasis. Chemotherapy is one of the main treatment strategies for solid tumors, while chemoresistance is the major limitation of the chemotherapy for patients with various types of cancer. A number of evidence indicate that TAMs can accumulate in tumors after chemotherapy and contribute to chemoresistance.
Methods
For the endocytic uptake of EGF we used flow cytometry analysis. Confocal microscopy was used for the analysis of stabilin-1-mediated internalization and endocytic trafficking of EGF in CHO cells and in modeled TAMs differentiated in the presence of conditioned supernatants of breast cancer (MCF-7) and colorectal cancer (Colo206F) cell lines. We performed next-generation sequencing of RNA samples obtained from our modeled TAMs. Validation of sequencing data by real-time PCR was performed for selected genes implicated in the endocytic uptake: DNM3, STX8, DENND1A and EHD1.
Results
For the first time we demonstrated that stabilin-1 ectopically expressed in CHO cells mediates endocytic uptake of EGF, key growth factor stimulating progression of breast and colorectal cancer. In the model of primary human TAMs, we have demonstrated that cisplatin decreases stabilin-1-mediated internalization and endocytic trafficking of EGF, without affecting gene expression of scavenger receptor stabilin-1. Molecular mechanisms of cisplatin effect on TAMs were uncovered using high throughput RNA sequencing. Gene set enrichment analysis identified that cisplatin contributes to defects in endocyting machinery reducing membrane biogenesis and vesicular transport. Significant suppression of DNM3, STX8, DENND1A and EHD1 genes expression by cisplatin was confirmed by RT-PCR.
Conclusions
We suggested that suppression of receptor-mediated clearance of tumor-supportive factors, such as EGF, by chemotherapeutic drugs may potentially lead to the tumor progression and/or relapse as a mechanism of macrophage-mediated chemoresistance. This study was supported by grand RSF №19-15-00151.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Research Tomsk State University.
Funding
RSF N19-15-00151.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract
4125 - DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone
Presenter: Ramon Mohanlal
Session: Poster Display session 1
Resources:
Abstract